

Ruey-Meei Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4764021/publications.pdf>

Version: 2024-02-01

132
papers

6,074
citations

94433

37
h-index

79698

73
g-index

134
all docs

134
docs citations

134
times ranked

7520
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of task prioritization on a postural-motor task in early-stage Parkinson's disease: EEG connectivity and clinical implication. <i>GeroScience</i> , 2022, 44, 2061-2075.	4.6	5
2	Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease. <i>European Journal of Neurology</i> , 2022, 29, 1044-1055.	3.3	10
3	Advanced brain aging in multiple system atrophy compared to Parkinson's disease. <i>NeuroImage: Clinical</i> , 2022, 34, 102997.	2.7	7
4	The Effects of Intensive Voice Treatment in Mandarin Speakers With Parkinson's Disease: Acoustic and Perceptual Findings. <i>American Journal of Speech-Language Pathology</i> , 2022, 31, 1354-1367.	1.8	2
5	<i>COQ2</i> and <i>SNCA</i> polymorphisms interact with environmental factors to modulate the risk of multiple system atrophy and subtype disposition. <i>European Journal of Neurology</i> , 2022, 29, 2956-2966.	3.3	2
6	Long-term efficacy of bilateral subthalamic deep brain stimulation in the parkinsonism of SCA 3: A rare case report. <i>European Journal of Neurology</i> , 2022, 29, 2544-2547.	3.3	8
7	Lack of PTRHD1 mutation in patients with young-onset and familial Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2021, 100, 118.e15-118.e16.	3.1	5
8	A Double-blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1229-1237.	3.9	22
9	Interactions of COMT and ALDH2 Genetic Polymorphisms on Symptoms of Parkinson's Disease. <i>Brain Sciences</i> , 2021, 11, 361.	2.3	9
10	Reply: UQCRC1 variants in Parkinson's disease: a large cohort study in Chinese mainland population. <i>Brain</i> , 2021, 144, e55-e55.	7.6	0
11	Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation: A Novel DARS2 Mutation and Intra-familial Heterogeneity. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1116-1122.	1.5	2
12	Alpha-Synuclein and Cognitive Decline in Parkinson Disease. <i>Life</i> , 2021, 11, 1239.	2.4	18
13	The role of noncoding RNAs in Parkinson's disease: biomarkers and associations with pathogenic pathways. <i>Journal of Biomedical Science</i> , 2021, 28, 78.	7.0	45
14	Updates on the Genetics of Parkinson's Disease: Clinical Implications and Future Treatment. <i>Acta Neurologica Taiwanica</i> , 2021, 30(3), 83-93.	0.3	3
15	Mitochondrial <i>UQCRC1</i> mutations cause autosomal dominant parkinsonism with polyneuropathy. <i>Brain</i> , 2020, 143, 3352-3373.	7.6	37
16	Attentional Resource Associated With Visual Feedback on a Postural Dual Task in Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2020, 34, 891-903.	2.9	2
17	Parkinson disease risk variants in East Asian populations. <i>Nature Reviews Neurology</i> , 2020, 16, 461-462.	10.1	3
18	The Effects of Task Prioritization on Dual-Tasking Postural Control in Patients With Parkinson Disease Who Have Different Postural Impairments. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, 1212-1219.	0.9	6

#	ARTICLE	IF	CITATIONS
19	Genetic analysis of PODXL gene in patients with familial and young-onset Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2019, 84, 235.e9-235.e10.	3.1	1
20	Modified Frameless Stereotactic System for Intracerebral Delivery of Viral Vector in Young Children. <i>Operative Neurosurgery</i> , 2019, 18, 166-174.	0.8	1
21	A clinical and genetic study of early-onset and familial parkinsonism in taiwan: An integrated approach combining gene dosage analysis and next-generation sequencing. <i>Movement Disorders</i> , 2019, 34, 506-515.	3.9	71
22	Effects of rhythmic auditory cueing on stepping in place in patients with Parkinson's disease. <i>Medicine (United States)</i> , 2019, 98, e17874.	1.0	10
23	Effect of ALDH2 on Sleep Disturbances in Patients with Parkinson's Disease. <i>Scientific Reports</i> , 2019, 9, 18950.	3.3	17
24	Acoustic and Perceptual Consequences of Speech Cues for Mandarin Speakers With Parkinson's Disease. <i>American Journal of Speech-Language Pathology</i> , 2019, 28, 521-535.	1.8	8
25	PINK1 Phosphorylates MIC60/Mitofilin to Control Structural Plasticity of Mitochondrial Crista Junctions. <i>Molecular Cell</i> , 2018, 69, 744-756.e6.	9.7	88
26	Does cigarette smoking do nothing but harm?. <i>Neurology</i> , 2018, 90, 307-308.	1.1	1
27	Improving Dual-Task Control With a Posture-Second Strategy in Early-Stage Parkinson Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 1540-1546.e2.	0.9	11
28	Control of the Motions of the Body's Center of Mass and End-Points of the Lower Limbs in Patients with Mild Parkinson's Disease During Obstacle-Crossing. <i>Journal of Medical and Biological Engineering</i> , 2018, 38, 534-543.	1.8	4
29	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018, 33, 1750-1759.	3.9	42
30	LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review. <i>Journal of Biomedical Science</i> , 2018, 25, 52.	7.0	29
31	PDE8B mutation is not associated with Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2018, 71, 265.e15-265.e16.	3.1	1
32	Analysis of GWAS-linked variants in multiple system atrophy. <i>Neurobiology of Aging</i> , 2018, 67, 201.e1-201.e4.	3.1	16
33	Cross-Cultural Differences of the Non-Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 68-77.	1.5	29
34	Acoustic and perceptual speech characteristics of native Mandarin speakers with Parkinson's disease. <i>Journal of the Acoustical Society of America</i> , 2017, 141, EL293-EL299.	1.1	27
35	Lack of TMEM230 mutations in patients with familial and sporadic Parkinson's disease in a Taiwanese population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 751-756.	1.7	9
36	Lack of RAB39B mutations in early-onset and familial Parkinson's disease in a Taiwanese cohort. <i>Neurobiology of Aging</i> , 2017, 50, 169.e3-169.e4.	3.1	9

#	ARTICLE	IF	CITATIONS
37	Test-retest reliability and minimal detectable change of the Beck Depression Inventory and the Taiwan Geriatric Depression Scale in patients with Parkinson's disease. PLoS ONE, 2017, 12, e0184823.	2.5	26
38	National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011. Parkinson's Disease, 2016, 2016, 1-8.	1.1	7
39	Aldehyde dehydrogenase 2 is associated with cognitive functions in patients with Parkinson's disease. Scientific Reports, 2016, 6, 30424.	3.3	27
40	Immediate Effects of Clock-Turn Strategy on the Pattern and Performance of Narrow Turning in Persons With Parkinson Disease. Journal of Neurologic Physical Therapy, 2016, 40, 249-256.	1.4	13
41	DCTN1 p.K56R in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 28, 56-61.	2.2	27
42	Clinical heterogeneity of LRRK2 p.I2012T mutation. Parkinsonism and Related Disorders, 2016, 33, 36-43.	2.2	17
43	Motion analysis of axial rotation and gait stability during turning in people with Parkinson's disease. Gait and Posture, 2016, 44, 83-88.	1.4	37
44	Pathophysiology of Small-Fiber Sensory System in Parkinson's Disease. Medicine (United States), 2016, 95, e3058.	1.0	21
45	Neurodegeneration with brain iron accumulation presenting motor trick and impaired motor cortical plasticity. Clinical Neurology and Neurosurgery, 2016, 141, 95-97.	1.4	0
46	Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3 β activity. Human Molecular Genetics, 2016, 25, 1965-1978.	2.9	45
47	Lack of CHCHD2 mutations in Parkinson's disease in a Taiwanese population. Neurobiology of Aging, 2016, 38, 218.e1-218.e2.	3.1	16
48	Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: A nationwide, population-based study. Journal of the Formosan Medical Association, 2016, 115, 531-538.	1.7	56
49	Home-based virtual reality balance training and conventional balance training in Parkinson's disease: A randomized controlled trial. Journal of the Formosan Medical Association, 2016, 115, 734-743.	1.7	123
50	Memory for gist and detail information in patients with Parkinson's disease. BMJ Open, 2015, 5, e009795.	1.9	19
51	COQ2 gene variants associate with cerebellar subtype of multiple system atrophy in Chinese. Movement Disorders, 2015, 30, 436-437.	3.9	36
52	The impact of nonmotor symptoms on quality of life in patients with Parkinson's disease in Taiwan. Neuropsychiatric Disease and Treatment, 2015, 11, 2865.	2.2	31
53	The impact of nocturnal disturbances on daily quality of life in patients with Parkinson's disease. Neuropsychiatric Disease and Treatment, 2015, 11, 2005.	2.2	15
54	Dynamic Trk and G Protein Signalings Regulate Dopaminergic Neurodifferentiation in Human Trophoblast Stem Cells. PLoS ONE, 2015, 10, e0143852.	2.5	10

#	ARTICLE	IF	CITATIONS
55	Lrrk regulates the dynamic profile of dendritic Golgi outposts through the golgin Lava lamp. <i>Journal of Cell Biology</i> , 2015, 210, 471-483.	5.2	46
56	Mutational analysis of SYNJ1 gene (PARK20) in Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2015, 36, 2905.e7-2905.e8.	3.1	13
57	Biomarkers of cognitive decline in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 431-443.	2.2	71
58	COQ2 p.V393A variant, rs148156462, is not associated with Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2015, 36, 546.e17-546.e18.	3.1	4
59	Antihypertensive Agents and Risk of Parkinson's Disease: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2014, 9, e98961.	2.5	74
60	Mutational Analysis of Angiogenin Gene in Parkinson's Disease. <i>PLoS ONE</i> , 2014, 9, e112661.	2.5	6
61	Lack of C9orf72 Repeat Expansion in Taiwanese Patients with Mixed Neurodegenerative Disorders. <i>Frontiers in Neurology</i> , 2014, 5, 59.	2.4	15
62	DNAJC13 mutations in Parkinson disease. <i>Human Molecular Genetics</i> , 2014, 23, 1794-1801.	2.9	258
63	The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. <i>Neurobiology of Aging</i> , 2014, 35, 266.e5-266.e14.	3.1	36
64	BST1 rs11724635 interacts with environmental factors to increase the risk of Parkinson's disease in a Taiwanese population. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 280-283.	2.2	28
65	Risk of Parkinson's disease following severe constipation: A nationwide population-based cohort study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1371-1375.	2.2	97
66	Vitamin D receptor genetic variants and Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2014, 35, 1212.e11-1212.e13.	3.1	31
67	Application of the University of Pennsylvania Smell Identification Test (Traditional Chinese Version) for Detecting Olfactory Deficits in Early Parkinson's Disease in a Taiwanese Cohort. <i>Journal of Parkinson's Disease</i> , 2014, 4, 175-180.	2.8	14
68	Population-specific frequencies for <i>LRRK2</i> susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO-PD) consortium. <i>Movement Disorders</i> , 2013, 28, 1740-1744.	3.9	30
69	Social brain dysfunctions in patients with Parkinson's disease: a review of theory of mind studies. <i>Translational Neurodegeneration</i> , 2013, 2, 7.	8.0	23
70	Mystery Case: Hemiballism in a patient with parietal lobe infarction. <i>Neurology</i> , 2013, 80, e22.	1.1	4
71	Predictors of road crossing safety in pedestrians with Parkinson's disease. <i>Accident Analysis and Prevention</i> , 2013, 51, 202-207.	5.7	11
72	RIT2 variant is not associated with Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2013, 34, 2236.e1-2236.e3.	3.1	11

#	ARTICLE	IF	CITATIONS
73	STX6 rs1411478 is not associated with increased risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 563-565.	2.2	16
74	Mutational analysis of FBXO7 gene in Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2013, 34, 1713.e1-1713.e4.	3.1	18
75	Increase of oxidative stress by a novel PINK1 mutation, P209A. <i>Free Radical Biology and Medicine</i> , 2013, 58, 160-169.	2.9	19
76	Discontinuation of statin therapy associates with Parkinson disease. <i>Neurology</i> , 2013, 81, 410-416.	1.1	110
77	Reaffirmation of GAK, but not HLA-DRA, as a Parkinson's disease susceptibility gene in a Taiwanese population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 841-846.	1.7	14
78	Dopaminergic Neuronal Imaging in Genetic Parkinson's Disease: Insights into Pathogenesis. <i>PLoS ONE</i> , 2013, 8, e69190.	2.5	55
79	Advanced Theory of Mind in patients at early stage of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 21-24.	2.2	42
80	Neuropsychological profile in patients with early stage of Parkinson's disease in Taiwan. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1067-1072.	2.2	40
81	Pulsed Wave Doppler Ultrasound Is Useful to Assess Vasomotor Response in Patients with Multiple System Atrophy and Well Correlated with Tilt Table Study. <i>Scientific World Journal</i> , The, 2012, 2012, 1-8.	2.1	1
82	Gene Therapy for Aromatic L-Amino Acid Decarboxylase Deficiency. <i>Science Translational Medicine</i> , 2012, 4, 134ra61.	12.4	195
83	PLA2G6 mutations in PARK1-linked young-onset parkinsonism and sporadic Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2012, 159B, 183-191.	1.7	71
84	Psychotic-affective symptoms and multiple system atrophy expand phenotypes of spinocerebellar ataxia type 2. <i>BMJ Case Reports</i> , 2012, 2012, bcr1020115061-bcr1020115061.	0.5	6
85	Ectopic Pregnancy-Derived Human Trophoblastic Stem Cells Regenerate Dopaminergic Nigrostriatal Pathway to Treat Parkinsonian Rats. <i>PLoS ONE</i> , 2012, 7, e52491.	2.5	8
86	Lrrk2 S1647T and BDNF V66M interact with environmental factors to increase risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 84-88.	2.2	38
87	Meige Syndrome Relieved by Bilateral Pallidal Stimulation With Cycling Mode. <i>Neurosurgery</i> , 2011, 69, E1333-E1337.	1.1	20
88	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. <i>Lancet Neurology</i> , The, 2011, 10, 898-908.	10.2	294
89	VPS35 Mutations in Parkinson Disease. <i>American Journal of Human Genetics</i> , 2011, 89, 162-167.	6.2	747
90	VPS35 Mutations in Parkinson Disease. <i>American Journal of Human Genetics</i> , 2011, 89, 347.	6.2	3

#	ARTICLE	IF	CITATIONS
91	Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria. <i>Human Genetics</i> , 2011, 130, 817-827.	3.8	54
92	Minimal Detectable Change of the Timed Up & Go Test and the Dynamic Gait Index in People With Parkinson Disease. <i>Physical Therapy</i> , 2011, 91, 114-121.	2.4	275
93	LRRK2 Parkinson's disease: from animal models to cellular mechanisms. <i>Reviews in the Neurosciences</i> , 2011, 22, 411-8.	2.9	9
94	Effects of Virtual Reality-Augmented Balance Training on Sensory Organization and Attentional Demand for Postural Control in People With Parkinson Disease: A Randomized Controlled Trial. <i>Physical Therapy</i> , 2011, 91, 862-874.	2.4	157
95	Feeling of knowing in episodic memory in patients with Parkinson's disease with various motor symptoms. <i>Movement Disorders</i> , 2010, 25, 1034-1039.	3.9	18
96	Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. <i>Human Mutation</i> , 2010, 31, n/a-n/a.	2.5	106
97	Association of pyridoxal kinase and Parkinson disease. <i>Annals of Neurology</i> , 2010, 67, 409-411.	5.3	9
98	Rapid screening of ATP13A2 variant with high-resolution melting analysis. <i>Movement Disorders</i> , 2010, 25, 2434-2437.	3.9	9
99	LRRK2 G2019S Mutation Induces Dendrite Degeneration through Mislocalization and Phosphorylation of Tau by Recruiting Autoactivated GSK3 β . <i>Journal of Neuroscience</i> , 2010, 30, 13138-13149.	3.6	153
100	O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. <i>Lung Cancer</i> , 2010, 68, 484-490.	2.0	29
101	A novel neuropsychiatric phenotype of KCNJ2 mutation in one Taiwanese family with Andersen-Tawil syndrome. <i>Journal of Human Genetics</i> , 2010, 55, 186-188.	2.3	25
102	Genotype-phenotype correlates in Taiwanese patients with early-onset recessive parkinsonism. <i>Movement Disorders</i> , 2009, 24, 104-108.	3.9	24
103	GCH1 in early-onset Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2070-2075.	3.9	17
104	Non-synonymous GIGYF2 variants in Parkinson's disease from two Asian populations. <i>Human Genetics</i> , 2009, 126, 425-430.	3.8	17
105	Lack of evidence for association of a parkin promoter polymorphism with early-onset Parkinson's disease in a Chinese population. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 149-152.	2.2	3
106	Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 466-467.	2.2	31
107	Focal brain glucose hypermetabolism in myoclonus-dystonia syndrome caused by an epsilon-sarcoglycan gene mutation. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 614-616.	2.2	4
108	Analysis of Parkin Co-Regulated Gene in a Taiwanese Ethnic Chinese cohort with early-onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 417-421.	2.2	8

#	ARTICLE	IF	CITATIONS
109	LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. <i>Journal of Biomedical Science</i> , 2008, 15, 661-7.	7.0	50
110	Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. <i>Annals of Neurology</i> , 2008, 64, 88-92.	5.3	207
111	Lrrk2 R1628P in non-Chinese Asian races. <i>Annals of Neurology</i> , 2008, 64, 472-473.	5.3	26
112	Neurocysticercosis Presenting with Epilepsia Partialis Continua: A Clinicopathologic Report and Literature Review. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 576-581.	1.7	8
113	Overexpression of Heme Oxygenase-1 Protects Dopaminergic Neurons against 1-Methyl-4-Phenylpyridinium-Induced Neurotoxicity. <i>Molecular Pharmacology</i> , 2008, 74, 1564-1575.	2.3	122
114	The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 246-249.	2.2	62
115	Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 89-92.	2.2	191
116	Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson's disease. <i>Clinica Chimica Acta</i> , 2007, 378, 136-141.	1.1	79
117	Lack of mutations in spinocerebellar ataxia type 2 and 3 genes in a Taiwanese (ethnic Chinese) cohort of familial and early-onset parkinsonism. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 434-438.	1.7	8
118	Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 550-555.	3.9	75
119	Common variants in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 899-900.	3.9	4
120	Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. <i>Journal of Neurology</i> , 2007, 254, 501-507.	3.6	68
121	Lrrk2 pathogenic substitutions in Parkinson's disease. <i>Neurogenetics</i> , 2005, 6, 171-177.	1.4	237
122	Parkin Mutations and Early-Onset Parkinsonism in a Taiwanese Cohort. <i>Archives of Neurology</i> , 2005, 62, 82.	4.5	84
123	Lack of mutations in DJ-1 in a cohort of Taiwanese ethnic Chinese with early-onset parkinsonism. <i>Movement Disorders</i> , 2004, 19, 1065-1069.	3.9	27
124	Selegiline (L-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders-A Lesson from MAO Inhibition. <i>Current Medicinal Chemistry - Central Nervous System Agents</i> , 2004, 4, 255-267.	0.5	4
125	Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations. <i>Movement Disorders</i> , 2002, 17, 670-675.	3.9	44
126	Evaluation of L-DOPA biotransformation during repeated L-DOPA infusion into the striatum in freely-moving young and old rats. <i>Developmental Brain Research</i> , 2000, 121, 123-131.	1.7	2

#	ARTICLE	IF	CITATIONS
127	Effect of MAO-B Inhibitors on MPP ⁺ Toxicity <i>in Vivo</i> . Annals of the New York Academy of Sciences, 2000, 899, 255-261.	3.8	40
128	CPP antagonizes hypoxia-induced changes in dopamine metabolism in the striatum of newborn rat. Neuroscience Research, 1999, 35, 347-350.	1.9	3
129	Suppression of Hydroxyl Radical Formation and Protection of Nigral Neurons by l-Deprenyl (Selegiline). Annals of the New York Academy of Sciences, 1996, 786, 379-390.	3.8	41
130	Antioxidant Mechanism and Protection of Nigral Neurons Against MPP ⁺ Toxicity by Deprenyl (Selegiline). Annals of the New York Academy of Sciences, 1994, 738, 214-221.	3.8	55
131	Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP ⁺ in vivo. European Journal of Pharmacology, 1993, 243, 241-247.	3.5	134
132	Attentional focus effect on dual-task walking in Parkinson's disease with and without freezing of gait. GeroScience, 0, , .	4.6	0